A Phase 1 interventional study of LP-001 Dose 1 (Single) and LP-001 Dose 2 (Single) in Myelodysplastic Syndrome (MDS), sponsored by Longbio Pharma. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-15.
Sponsored by Longbio Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 117 studies in Myelodysplastic Syndromes with a site in China — 55 open to participants now, 62 under way, 7 of them phase 3. Myelodysplastic Syndromes · China.
Among the 117 studies in Myelodysplastic Syndromes with a site in China, this one is the 56th largest by enrollment of the 102 interventional ones that give a count, is one of 9 that started in 2022, is one of 19 in phase 1, and was the 89th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →55 of the 117 studies in Myelodysplastic Syndromes with a site in China are open now. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70
Peking University People's Hospital · Sites in China
Ages 18–65
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Sites in China
Ages 18+
Fujian Medical University Union Hospital · Sites in China
Ages 14–60
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
117 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 60 · Phase 3 21 · Phase 4 4
First in 2003; this study’s year is marked. 9 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 76 across the 102 interventional studies, 250 across the 15 observational. Of the 27 that completed or were terminated, 9 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 117 have an industry lead sponsor. The 10 most frequent:
Longbio Pharma is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Longbio Pharma has 1 study filed under Myelodysplastic Syndromes — fewer than ten, so there is no comparison to draw.
13 of the studies in Myelodysplastic Syndromes with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04401748Phase 3AbbVieStudy Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | 2027-07 |
| NCT06304103Kind Pharmaceuticals LLCA Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome | 2026-12 |
| NCT04428489The First Affiliated Hospital of Soochow UniversityFollow-up Study of ICUS and CCUS Patients | 2026-12-31 |
| NCT07449286Peking University People's HospitalIFN-α in Relapse Prevention. | 2026-12-31 |
| NCT06378437Hangzhou GluBio Pharmaceutical Co., Ltd.A Study of GLB-001 in Patients With Myeloid Malignancies | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 117 studies in Myelodysplastic Syndromes with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-001 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-001 and Part 2, multiple ascending dose (MAD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose administration of LP-001 with dose 1
Biological: LP-001 Dose 1 (Single)
Single dose administration of LP-001 with dose 2
Biological: LP-001 Dose 2 (Single)
Single dose administration of LP-001 with dose 3
Biological: LP-001 Dose 3 (Single)
Single dose administration of LP-001 with dose 4
Biological: LP-001 Dose 4 (Single)
Single dose administration of LP-001 with dose 5
Biological: LP-001 Dose 5 (Single)
Single dose administration of LP-001 with dose 6
Biological: LP-001 Dose 6 (Single)
Single dose administration of placebo drug
Biological: Placebo (Single)
LP-001 with dose 7 was administered 4 times in total
Biological: LP-001 Dose 7 (Multiple)
LP-001 with dose 8 was administered 4 times in total
Biological: LP-001 Dose 8 (Multiple)
Placebo drug was administered 4 times in total
Biological: Placebo (Multiple)
A single dose of LP-001 (Dose 1) was administered subcutaneously.
A single dose of LP-001 (Dose 2) was administered subcutaneously.
A single dose of LP-001 (Dose 3) was administered subcutaneously.
A single dose of LP-001 (Dose 4) was administered subcutaneously.
A single dose of LP-001 (Dose 5) was administered subcutaneously.
A single dose of LP-001 (Dose 6) was administered subcutaneously.
A single dose of placebo was administered subcutaneously.
LP-001 (Dose 7) was administered multiple times subcutaneously.
LP-001 (Dose 8) was administered multiple times subcutaneously.
Placebo was administered multiple times subcutaneously.
Adverse events
Number of subjects with treatment-related Treatment Emergent Adverse Events (TEAEs).
Time frame: Observation for 36 days after administration
Time to peak concentration (Tmax) of LP-001
The time when the blood drug concentration reaches its peak after a single dose of medication.
Time frame: Observation for 36 days after administration
Maximum concentration (Cmax) of LP-001
The maximum concentration of LP-001 in the bloodstream after administration.
Time frame: Observation for 36 days after administration
Elimination half-life (t1/2) of LP-001
The time required for the concentration of LP-005 in the bloodstream to decrease by half.
Time frame: Observation for 36 days after administration
Area under the concentration-time curve (AUC0-t) of LP-001
The time required for the concentration of LP-005 in the bloodstream to decrease by half.
Time frame: Observation for 36 days after administration
Apparent clearance rate (CL/F) of LP-001
The ratio of drug clearance to drug concentration, represents the apparent clearance of a drug after administration, adjusted for bioavailability.
Time frame: Observation for 36 days after administration
Assessment of immunogenicity
The proportion of anti drug antibody (ADA) positive subjects at different detection time points.
Time frame: Observation for 36 days after administration
Assessment of hemoglobin (Hb) change
Concentration of Hemoglobin changes from baseline at various time points of assessment.
Time frame: Observation for 36 days after administration
Assessment of red blood cell (RBC) count change
The count of RBC changes from baseline at various time points of assessment.
Time frame: Observation for 36 days after administration
Assessment of reticulocyte (Rtc) count change
The count of Rtc changes from baseline at various time points of assessment.
Time frame: Observation for 36 days after administration
Ran from Sep 2022 to primary completion in Aug 2023, 11 months.
Of 84 industry-sponsored phase 1 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 11 months is below that.
Counting every sponsor, half of 220 studies reached it within 52 months; a quarter within 31 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Longbio Pharma